Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial
- PMID: 35133415
- PMCID: PMC8826179
- DOI: 10.1001/jama.2022.0078
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial
Abstract
Importance: The effects of tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, as an addition to insulin glargine for treatment of type 2 diabetes have not been described.
Objective: To assess the efficacy and safety of tirzepatide added to insulin glargine in patients with type 2 diabetes with inadequate glycemic control.
Design, setting, and participants: Randomized phase 3 clinical trial conducted at 45 medical research centers and hospitals in 8 countries (enrollment from August 30, 2019, to March 20, 2020; follow-up completed January 13, 2021) in 475 adults with type 2 diabetes and inadequate glycemic control while treated with once-daily insulin glargine with or without metformin.
Interventions: Patients were randomized in a 1:1:1:1 ratio to receive once-weekly subcutaneous injections of 5-mg (n = 116), 10-mg (n = 119), or 15-mg (n = 120) tirzepatide or volume-matched placebo (n = 120) over 40 weeks. Tirzepatide was initiated at 2.5 mg/week and escalated by 2.5 mg every 4 weeks until the assigned dose was achieved.
Main outcomes and measures: The primary end point was mean change from baseline in glycated hemoglobin A1c (HbA1c) at week 40. The 5 key secondary end points included mean change in body weight and percentage of patients achieving prespecified HbA1c levels.
Results: Among 475 randomized participants (211 [44%] women; mean [SD] age, 60.6 [9.9] years; mean [SD] HbA1c, 8.31% [0.85%]), 451 (94.9%) completed the trial. Treatment was prematurely discontinued by 10% of participants in the 5-mg tirzepatide group, 12% in the 10-mg tirzepatide group, 18% in the 15-mg tirzepatide group, and 3% in the placebo group. At week 40, mean HbA1c change from baseline was -2.40% with 10-mg tirzepatide and -2.34% with 15-mg tirzepatide vs -0.86% with placebo (10 mg: difference vs placebo, -1.53% [97.5% CI, -1.80% to -1.27%]; 15 mg: difference vs placebo, -1.47% [97.5% CI, -1.75% to -1.20%]; P < .001 for both). Mean HbA1c change from baseline was -2.11% with 5-mg tirzepatide (difference vs placebo, -1.24% [95% CI, -1.48% to -1.01%]; P < .001]). Mean body weight change from baseline was -5.4 kg with 5-mg tirzepatide, -7.5 kg with 10-mg tirzepatide, -8.8 kg with 15-mg tirzepatide and 1.6 kg with placebo (5 mg: difference, -7.1 kg [95% CI, -8.7 to -5.4]; 10 mg: difference, -9.1 kg [95% CI, -10.7 to -7.5]; 15 mg: difference, -10.5 kg [95% CI, -12.1 to -8.8]; P < .001 for all). Higher percentages of patients treated with tirzepatide vs those treated with placebo had HbA1c less than 7% (85%-90% vs 34%; P < .001 for all). The most common treatment-emergent adverse events in the tirzepatide groups vs placebo group were diarrhea (12%-21% vs 10%) and nausea (13%-18% vs 3%).
Conclusions and relevance: Among patients with type 2 diabetes and inadequate glycemic control despite treatment with insulin glargine, the addition of subcutaneous tirzepatide, compared with placebo, to titrated insulin glargine resulted in statistically significant improvements in glycemic control after 40 weeks.
Trial registration: ClinicalTrials.gov Identifier: NCT04039503.
Conflict of interest statement
Figures
Comment in
-
Tirzepatide for Patients With Type 2 Diabetes.JAMA. 2022 Feb 8;327(6):529-530. doi: 10.1001/jama.2021.25016. JAMA. 2022. PMID: 35133426 No abstract available.
Similar articles
-
Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial.JAMA. 2023 Nov 7;330(17):1631-1640. doi: 10.1001/jama.2023.20294. JAMA. 2023. PMID: 37786396 Free PMC article. Clinical Trial.
-
Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice.Ann Pharmacother. 2023 Jul;57(7):822-836. doi: 10.1177/10600280221134127. Epub 2022 Nov 11. Ann Pharmacother. 2023. PMID: 36367094 Review.
-
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.Diabetologia. 2022 Aug;65(8):1251-1261. doi: 10.1007/s00125-022-05715-4. Epub 2022 May 17. Diabetologia. 2022. PMID: 35579691 Free PMC article. Review.
-
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.Lancet. 2021 Aug 14;398(10300):583-598. doi: 10.1016/S0140-6736(21)01443-4. Epub 2021 Aug 6. Lancet. 2021. PMID: 34370970 Clinical Trial.
-
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25. N Engl J Med. 2021. PMID: 34170647 Clinical Trial.
Cited by
-
GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes.Acta Diabetol. 2024 Jun 3. doi: 10.1007/s00592-024-02300-6. Online ahead of print. Acta Diabetol. 2024. PMID: 38831203 Review.
-
GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?Curr Atheroscler Rep. 2024 Aug;26(8):341-351. doi: 10.1007/s11883-024-01214-6. Epub 2024 May 29. Curr Atheroscler Rep. 2024. PMID: 38809399 Review.
-
Female obesity: clinical and psychological assessment toward the best treatment.Front Endocrinol (Lausanne). 2024 May 3;15:1349794. doi: 10.3389/fendo.2024.1349794. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38765954 Free PMC article. Review.
-
Use of Tirzepatide in Adults with Type 2 Diabetes Mellitus: Scientific Evidence and Practical Aspects.Diabetes Ther. 2024 Jul;15(7):1501-1512. doi: 10.1007/s13300-024-01587-6. Epub 2024 May 9. Diabetes Ther. 2024. PMID: 38722495 Free PMC article. Review.
-
Therapeutic advances in obesity management: an overview of the therapeutic interventions.Front Endocrinol (Lausanne). 2024 Apr 23;15:1364503. doi: 10.3389/fendo.2024.1364503. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38715796 Free PMC article. Review.
References
-
- Pozzilli P, Norwood P, Jódar E, et al. . Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9). Diabetes Obes Metab. 2017;19(7):1024-1031. doi:10.1111/dom.12937 - DOI - PubMed
-
- Zinman B, Aroda VR, Buse JB, et al. ; PIONEER 8 Investigators . Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial. Diabetes Care. 2019;42(12):2262-2271. doi:10.2337/dc19-0898 - DOI - PMC - PubMed
-
- Rosenstock J, Nino A, Soffer J, et al. . Impact of a weekly glucagon-like peptide 1 receptor agonist, albiglutide, on glycemic control and on reducing prandial insulin use in type 2 diabetes inadequately controlled on multiple insulin therapy: a randomized trial. Diabetes Care. 2020;43(10):2509-2518. doi:10.2337/dc19-2316 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical